Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors

V. Nardi, T. Raz, X. Cao, C. J. Wu, R. M. Stone, J. Cortes, M. W.N. Deininger, G. Church, J. Zhu, G. Q. Daley

Research output: Contribution to journalArticle

Abstract

Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10-4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.

Original languageEnglish (US)
Pages (from-to)775-782
Number of pages8
JournalOncogene
Volume27
Issue number6
DOIs
StatePublished - Jan 31 2008
Externally publishedYes

Fingerprint

Phosphotransferases
Mutation
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenes
Point Mutation
Pharmaceutical Preparations
Recurrence
Drug Therapy
Research
Proteins

Keywords

  • Drug resistance
  • Mutations detection
  • Solid-phase PCR

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. / Nardi, V.; Raz, T.; Cao, X.; Wu, C. J.; Stone, R. M.; Cortes, J.; Deininger, M. W.N.; Church, G.; Zhu, J.; Daley, G. Q.

In: Oncogene, Vol. 27, No. 6, 31.01.2008, p. 775-782.

Research output: Contribution to journalArticle

Nardi, V, Raz, T, Cao, X, Wu, CJ, Stone, RM, Cortes, J, Deininger, MWN, Church, G, Zhu, J & Daley, GQ 2008, 'Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors', Oncogene, vol. 27, no. 6, pp. 775-782. https://doi.org/10.1038/sj.onc.1210698
Nardi, V. ; Raz, T. ; Cao, X. ; Wu, C. J. ; Stone, R. M. ; Cortes, J. ; Deininger, M. W.N. ; Church, G. ; Zhu, J. ; Daley, G. Q. / Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. In: Oncogene. 2008 ; Vol. 27, No. 6. pp. 775-782.
@article{9dae2d46e4f94db19eb9e56914e24adb,
title = "Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors",
abstract = "Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10-4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.",
keywords = "Drug resistance, Mutations detection, Solid-phase PCR",
author = "V. Nardi and T. Raz and X. Cao and Wu, {C. J.} and Stone, {R. M.} and J. Cortes and Deininger, {M. W.N.} and G. Church and J. Zhu and Daley, {G. Q.}",
year = "2008",
month = "1",
day = "31",
doi = "10.1038/sj.onc.1210698",
language = "English (US)",
volume = "27",
pages = "775--782",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors

AU - Nardi, V.

AU - Raz, T.

AU - Cao, X.

AU - Wu, C. J.

AU - Stone, R. M.

AU - Cortes, J.

AU - Deininger, M. W.N.

AU - Church, G.

AU - Zhu, J.

AU - Daley, G. Q.

PY - 2008/1/31

Y1 - 2008/1/31

N2 - Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10-4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.

AB - Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10-4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.

KW - Drug resistance

KW - Mutations detection

KW - Solid-phase PCR

UR - http://www.scopus.com/inward/record.url?scp=38749145172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749145172&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210698

DO - 10.1038/sj.onc.1210698

M3 - Article

C2 - 17684485

AN - SCOPUS:38749145172

VL - 27

SP - 775

EP - 782

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 6

ER -